AOP-Wiki

API

All Key Events

Showing 1901 to 1923 of 1923 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

2406	Increase, Regenerative nodule formation Short Name Increase, Regenerative nodule formation	0	Tissue	Feb 10, 2026	Feb 10, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2407	Increase, Cirrhosis Short Name Increase, Cirrhosis	0	Organ	Feb 10, 2026	Feb 11, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2408	Increase, Adipose lipolysis Short Name Increase, Adipose lipolysis	0	Tissue	Feb 10, 2026	Feb 10, 2026	3 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress
2409	Decrease, 11β-Hydroxysteroid dehydrogenase type 2 activity Short Name Decrease, 11β-HSD2 activity	0	Molecular	Feb 10, 2026	Feb 26, 2026	630: Decreased 11β-Hydroxysteroid dehydrogenase type 2 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction
2410	Increase, 11β-Hydroxysteroid dehydrogenase type 1 activity Short Name Increase, 11β-HSD1 activity	0	Molecular	Feb 18, 2026	Feb 18, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2411	Increase, Circulating active glucocorticoid availability Short Name	0	Organ	Feb 18, 2026	Feb 24, 2026	None
2412	Increase, Hepatic intracellular active glucocorticoids Short Name	0	Cellular	Feb 18, 2026	Feb 26, 2026	6 AOPs 624: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated mitochondrial dysfunction 625: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated oxidative stress 626: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via insulin resistance-associated endoplasmic reticulum stress 627: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated mitochondrial dysfunction 628: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated oxidative stress 629: Increased 11β-Hydroxysteroid dehydrogenase type 1 activity leading to MASLD progression via lipogenesis-associated endoplasmic reticulum stress
2413	Increased, uterine weight Short Name Increased, uterine weight	1	Organ	Mar 13, 2026	Mar 13, 2026	637: Activation, estrogen receptor alpha leads to increased uterine weight via earlier proliferation of cells of the uterine lining
2414	COL3A1 Signaling Pathway Short Name COL3A1 Signaling Pathway	0	Molecular	Mar 25, 2026	Mar 25, 2026	638: Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis
2415	Precocious puberty Short Name Precocious puberty	1	Individual	Mar 26, 2026	Mar 26, 2026	639: Activation, estrogen receptor alpha leads to precocious puberty via increased kisspeptin release
2416	human amyotrophic lateral sclerosis (ALS) Short Name ALS	0	Individual	Mar 30, 2026	Mar 30, 2026	636: Increase in reactive oxygen species (ROS) leading to human amyotrophic lateral sclerosis (ALS)
2417	Increased, differentiation to ovaries Short Name Increased, differentiation to ovaries	1	Individual	Apr 17, 2026	Apr 17, 2026	641: Activation, estrogen receptor alpha leads to increased, phenotypic female-biased sex ratio via increased, differentiation to ovaries
2418	Increased, phenotypic female-biased sex ratio Short Name Increased, female-biased sex ratio	1	Population	Apr 17, 2026	Apr 17, 2026	641: Activation, estrogen receptor alpha leads to increased, phenotypic female-biased sex ratio via increased, differentiation to ovaries
2419	Decreased, Retinoic Acid Receptor Activation Short Name Decreased, RAR activation	0	Tissue	Apr 22, 2026	Apr 23, 2026	398: Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia
2420	Increased, Retinoic Acid Receptor Activation Short Name Increased, RAR activation	0	Tissue	Apr 22, 2026	Apr 23, 2026	400: Inhibition of CYP26B1 activity in fetal testis leading to reduced fertility
2421	Inhibition, Intestinal FXR Short Name FXR inhibition	0	Molecular	Apr 22, 2026	Apr 22, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2422	Ileal FGF15/FGF19 secretion, decreased Short Name Decreased FGF15/FGF19	0	Cellular	Apr 22, 2026	Apr 22, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2423	Hepatic SHP, decreased Short Name Hepatic SHP, decreased	0	Cellular	Apr 22, 2026	Apr 22, 2026	None
2424	Hepatic CYP7A1, increased Short Name Hepatic CYP7A1, increased	0	Cellular	Apr 22, 2026	Apr 22, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2425	Intrahepatic bile acid burden, increased Short Name Intrahepatic bile acids, increased	0	Cellular	Apr 23, 2026	Apr 23, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2426	Hepatic BSEP (ABCB11), decreased Short Name BSEP (ABCB11), decreased	0	Cellular	Apr 23, 2026	Apr 23, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2427	Bile acid composition in bile and intestine, altered Short Name Bile acid composition, altered	0	Cellular	Apr 23, 2026	Apr 23, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation
2428	Gut derived PAMPs, increased Short Name PAMPs, increased	0	Cellular	Apr 23, 2026	Apr 23, 2026	642: Intestinal FXR inhibition leading to steatohepatitis via gut‑liver axis dysregulation